Affinage

ARID1A

AT-rich interactive domain-containing protein 1A · UniProt O14497

Length
2285 aa
Mass
242.0 kDa
Annotated
2026-04-28
100 papers in source corpus 38 papers cited in narrative 38 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ARID1A is the signature subunit of the BAF (SWI/SNF-A) chromatin remodeling complex, functioning as a central integrator of chromatin accessibility control across cell fate determination, DNA damage repair, metabolic regulation, and immune signaling. Through its non-sequence-specific ARID DNA-binding domain and C-terminal ARM-repeat scaffold, ARID1A recruits BRG1 and lineage-specific transcription factors (including FOXA1/ER, PU.1/NF-κB, IRF4, OCT4/β-catenin, and PGR-A) to promoters and enhancers, where it modulates H3K27ac and chromatin accessibility to activate or repress target genes controlling cell cycle arrest (p21), pluripotency, cardiac differentiation, and metabolic pathways such as glutaminolysis and the mevalonate pathway (PMID:10757798, PMID:16230384, PMID:22621927, PMID:31913353, PMID:38458187, PMID:34085048, PMID:36963401). ARID1A is directly recruited to DNA double-strand breaks via ATR, where it facilitates end resection, recruits RAD21/CTCF for chromatin loop formation, silences transcription through HDAC1/RSF1, and drives m6A-dependent R-loop resolution by recruiting METTL3/METTL14 and RNase H1 (PMID:26069190, PMID:38587186, PMID:38358891). ARID1A protein stability is regulated by IKKβ-mediated phosphorylation triggering β-TRCP degradation, mTORC1-driven ubiquitination, TRIM32 stabilization, and USP11-dependent destabilization, and ARID1A physically antagonizes EZH2-mediated PRC2 silencing of interferon-responsive genes and sequesters YAP/TAZ from TEAD to suppress proliferation (PMID:36435834, PMID:34429326, PMID:31914402, PMID:32027624, PMID:37543677).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1998 High

    Establishing ARID1A as a bona fide SWI/SNF subunit resolved whether this large protein was an integral complex member or a transient interactor, anchoring all subsequent functional studies to the chromatin remodeling machinery.

    Evidence Co-immunoprecipitation and biochemical purification from multiple mammalian cell lines

    PMID:9584200

    Open questions at the time
    • Stoichiometry within distinct SWI/SNF subcomplexes not defined
    • No structural information on how ARID1A assembles into the complex
  2. 2000 High

    Demonstrating that ARID1A contains a non-sequence-specific DNA-binding ARID domain established the molecular basis for how SWI/SNF-A engages chromatin, distinguishing it from ARID1B-containing complexes.

    Evidence ARID domain characterization and in vitro DNA binding assays after biochemical purification

    PMID:10757798

    Open questions at the time
    • No structural resolution of ARID domain-DNA interaction
    • How non-sequence-specific binding achieves locus specificity unknown
  3. 2005 High

    Showing ARID1A is required for differentiation-induced cell cycle arrest and p21 upregulation established its tumor suppressor function and functional non-redundancy with ARID1B.

    Evidence siRNA knockdown in differentiating cells with BrdU incorporation and Western blotting for p21/cyclins

    PMID:16230384

    Open questions at the time
    • Direct ChIP at p21 locus not performed
    • Mechanism of ARID1A vs. ARID1B target specificity unclear
  4. 2008 High

    Genetic ablation in mouse ES cells revealed that ARID1A is essential for pluripotency maintenance and mesodermal lineage specification, establishing its role as a master regulator of early cell fate decisions.

    Evidence Conditional knockout mouse model with ES cell differentiation assays and microarray

    PMID:18448678

    Open questions at the time
    • Direct chromatin targets mediating pluripotency not mapped genome-wide
    • Relationship between ARID1A and other pluripotency TFs not fully resolved
  5. 2012 High

    Tissue-specific cardiac knockout demonstrated that ARID1A directly binds promoters of cardiac lineage genes (Mef2c, Nkx2.5, Bmp10) and recruits BRG1 to regulate chromatin accessibility, establishing the paradigm for how ARID1A targets SWI/SNF to lineage-determining loci.

    Evidence Conditional cardiac KO mouse with ChIP and DNase I hypersensitivity assays

    PMID:22621927

    Open questions at the time
    • Genome-wide binding profile not generated
    • How ARID1A selects cardiac vs. other lineage promoters not defined
  6. 2015 High

    Discovery that ARID1A is recruited to DNA double-strand breaks via ATR and facilitates DSB end processing opened an entirely new functional axis beyond transcription — direct participation in DNA damage repair — and explained the PARP inhibitor sensitivity of ARID1A-mutant cancers.

    Evidence Co-IP of ARID1A-ATR, laser-induced DSB recruitment imaging, end resection assays, in vivo PARP inhibitor sensitivity

    PMID:26069190

    Open questions at the time
    • Structural basis of ATR-ARID1A interaction unknown
    • Whether ARID1A chromatin remodeling activity is required at DSBs vs. scaffolding alone not separated
  7. 2017 High

    Demonstrating that ARID1A has context-dependent oncogenic (promoting tumor initiation via CYP450-mediated oxidative stress) and tumor-suppressive (maintaining chromatin accessibility for migration genes) roles in HCC resolved the paradox of ARID1A's dual behavior in cancer.

    Evidence Liver-specific conditional KO and overexpression mouse models with ATAC-seq and RNA-seq

    PMID:29136504

    Open questions at the time
    • Molecular switch determining oncogenic vs. suppressive function not identified
    • Stage-specific interactors not defined
  8. 2018 High

    Identification of ARID1A as a transcriptional repressor that recruits HDAC1 to enhancers in a FOXA1-dependent manner, with loss leading to BRD4-driven proliferation, established the ARID1A-HDAC1 repressive axis at cis-regulatory elements and explained sensitivity to BET inhibitors.

    Evidence Genome-wide CRISPR screen, ChIP-seq, ATAC-seq, and HDAC1 co-IP in breast cancer cells

    PMID:31913353 PMID:35390516

    Open questions at the time
    • Whether HDAC1 recruitment is universal or enhancer-class-specific not resolved
    • DUF3518 domain structure undetermined
  9. 2020 High

    Three contemporaneous studies established that ARID1A physically antagonizes EZH2 to maintain IFN-responsive gene accessibility, sequesters YAP/TAZ from TEAD to suppress proliferation, and targets SWI/SNF to ER/FOXA1/GATA3 luminal lineage sites — collectively defining ARID1A as a hub for opposing repressive chromatin states and oncogenic transcription factor programs.

    Evidence Co-IP of ARID1A-EZH2 and ARID1A-YAP/TAZ with ATAC-seq; epigenome CRISPR screen for ER degrader resistance

    PMID:31932695 PMID:32027624 PMID:37543677

    Open questions at the time
    • Whether EZH2 and YAP/TAZ interactions are simultaneous or mutually exclusive unknown
    • Structural basis of C-terminal EZH2 binding not resolved
  10. 2020 High

    Identifying IKKβ-mediated phosphorylation and β-TRCP-dependent degradation of ARID1A linked inflammatory signaling to SWI/SNF destabilization, while TRIM32/USP11 and mTORC1 ubiquitination pathways defined three independent post-translational control axes for ARID1A protein levels.

    Evidence Phosphorylation and ubiquitination assays, co-IP, conditional KO mice with immune readouts

    PMID:31914402 PMID:34429326 PMID:36435834

    Open questions at the time
    • Relative contribution of each degradation pathway in different tissues unknown
    • Phosphodegron site(s) for IKKβ not fully mapped
  11. 2021 High

    Demonstrating that ARID1A recruits RAD21/CTCF for chromatin looping and HDAC1/RSF1 for transcription silencing at DSBs, while its loss causes R-loop accumulation and replication stress, unified the transcription and DNA repair functions into a coherent chromatin maintenance model.

    Evidence ChIP-seq, ATAC-seq, proximity ligation, NHEJ/HR reporters, DRIP-seq in ARID1A KO cells

    PMID:33826602 PMID:38587186

    Open questions at the time
    • Whether ARID1A remodeling at DSBs uses the same SWI/SNF catalytic mechanism as at promoters is unclear
    • Order of RAD21/CTCF vs. HDAC1/RSF1 recruitment not resolved
  12. 2021 High

    Metabolic profiling showed ARID1A directly represses GLS1 and regulates PKM, establishing that SWI/SNF loss rewires cancer cell metabolism from glycolysis toward TCA cycle/glutamine dependence — creating exploitable synthetic lethalities.

    Evidence ChIP at GLS1/PKM, metabolic flux analysis, CRISPR synthetic lethality screens, orthotopic and PDX models

    PMID:34085048 PMID:37939712

    Open questions at the time
    • Full inventory of ARID1A-regulated metabolic genes unknown
    • Whether metabolic rewiring is tissue-specific not comprehensively tested
  13. 2024 High

    Discovery that ARID1A recognizes R-loops via ATM, recruits METTL3/14 to deposit m6A, and thereby enables RNase H1-mediated R-loop resolution established an RNA modification-dependent mechanism linking ARID1A to genome stability.

    Evidence Co-IP, m6A-seq, R-loop IF, RNase H1 recruitment assays, epistasis with METTL3/14 KO

    PMID:38358891

    Open questions at the time
    • Whether m6A deposition at R-loops is genome-wide or restricted to DSB-proximal sites not determined
    • Structural basis of ARID1A R-loop recognition unknown
  14. 2024 High

    Identification of ARID1A's prion-like domain driving liquid-liquid phase separation at enhancers, and its role in orchestrating PU.1/NF-κB binding and IRF4-dependent plasma cell differentiation, revealed that ARID1A organizes transcription factor hubs through both phase separation and direct protein-protein scaffolding.

    Evidence In vitro LLPS reconstitution, Hi-C, ChIP-seq/ATAC-seq, conditional KO in B cells with scRNA-seq, ARID1A-IRF4 co-IP

    PMID:38458187 PMID:38906156 PMID:39095374

    Open questions at the time
    • Whether phase separation is required for all ARID1A-dependent enhancer activation or specific to EWS/FLI1 contexts
    • Relationship between PrLD condensate formation and canonical BAF complex assembly not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • A comprehensive structural understanding of full-length ARID1A within the BAF complex, the rules governing its locus-specific recruitment, and the relative importance of its phase separation vs. scaffolding vs. chromatin remodeling activities across tissues remain unresolved.
  • No high-resolution structure of full-length ARID1A in complex with BAF
  • Molecular determinants of tissue-specific oncogenic vs. tumor-suppressive switching undefined
  • Whether ARID1A's DNA repair and transcriptional functions are mechanistically separable in vivo not tested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 9 GO:0060090 molecular adaptor activity 3 GO:0003677 DNA binding 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005634 nucleus 5 GO:0005694 chromosome 3
Pathway
R-HSA-4839726 Chromatin organization 8 R-HSA-74160 Gene expression (Transcription) 8 R-HSA-1266738 Developmental Biology 5 R-HSA-1643685 Disease 5 R-HSA-1430728 Metabolism 4 R-HSA-162582 Signal Transduction 4 R-HSA-73894 DNA Repair 4 R-HSA-168256 Immune System 3 R-HSA-1640170 Cell Cycle 2
Partners
ATRBRG1EZH2HDAC1IRF4METTL3PGRYAP1
Complex memberships
BAF (SWI/SNF-A) complex

Evidence

Reading pass · 38 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 p270/ARID1A is an integral subunit of human SWI/SNF complexes and contains a non-sequence-specific DNA-binding ARID domain, establishing it as a human counterpart of yeast SWI1. Co-purification from mammalian cells, biochemical fractionation, ARID domain characterization, DNA binding assay Molecular and cellular biology High 10757798
1998 p270/ARID1A is an integral member of the human SWI/SNF chromatin remodeling complex, co-purifying with SWI/SNF components. Co-immunoprecipitation, biochemical purification, antibody cross-reactivity analysis Molecular and cellular biology High 9584200
2005 p270/ARID1A is required for cell cycle arrest on differentiation induction; its depletion prevents up-regulation of p21 and down-regulation of cyclins/E2F-responsive products, demonstrating functional distinctness from ARID1B-containing complexes. siRNA knockdown, BrdU incorporation (DNA synthesis assay), Western blotting for p21 and cyclins Cancer research High 16230384
2008 BAF250a/ARID1A is required for ES cell pluripotency and self-renewal; its ablation promotes differentiation into primitive endoderm-like cells and blocks mesodermal layer formation in early mouse embryos. Conditional knockout mouse model, ES cell culture, DNA microarray, immunostaining, embryoid body differentiation assays Proceedings of the National Academy of Sciences of the United States of America High 18448678
2009 ARID1A/BAF250A physically interacts with the tumor suppressor HIC1 in a BRG1-dependent manner and is recruited to the E2F1 promoter in a repressive SWI/SNF complex; ARID1A does not interact with BRM. Yeast two-hybrid screen, co-immunoprecipitation in WI38 fibroblasts and BRG1-/- SW13 cells, sequential ChIP (ChIP-reChIP) Biochemical and biophysical research communications Medium 19486893
2010 BAF250/ARID1 (predominantly ARID1B isoform studies, but functional context applies to ARID1A) assembles with Elongin C, Cullin 2, and Roc1 into an E3 ubiquitin ligase that monoubiquitinates histone H2B at lysine 120 in vitro; Drosophila osa (BAF250 ortholog) or BAF250 RNAi depletion reduced global H2Bub. Immunopurification from mammalian cells, in vitro ubiquitination assay, RNAi in Drosophila and human cells Molecular and cellular biology Medium 20086098
2012 BAF250a/ARID1A regulates cardiac progenitor cell differentiation; conditional ablation in mouse second heart field causes trabeculation defects, ventricular septal defect, and embryonic lethality. Mechanistically, BAF250a binds to target gene promoters (Mef2c, Nkx2.5, Bmp10) and recruits BRG1 to modulate chromatin accessibility. Conditional knockout mouse, ES cell cardiomyocyte differentiation model, ChIP, DNase I hypersensitivity assay The Journal of biological chemistry High 22621927
2013 BAF250a/ARID1A deletion disrupts replication timing at specific chromosomal domains in ES cells, and BAF250a-deficient fibroblasts reprogrammed to pluripotency fail to reprogram replication timing in these same domains. Conditional knockout ES cells, Repli-seq (replication timing), esBAF ChIP Epigenetics & chromatin Medium 24330833
2014 Baf250a/ARID1A in the sinoatrial node activates Tbx3 expression and, together with Tbx3 and HDAC3, represses Nkx2.5; disruption of this pathway switches on contractile cardiomyocyte programming in the SAN, causing sick sinus disease. SAN-specific conditional knockout mouse, gene expression time-series analysis, ChIP, functional cardiac assays Cell research High 25145359
2015 ARID1A is recruited to DNA double-strand breaks via interaction with the ATR kinase; it facilitates processing of DSBs to single-strand ends and sustains DNA damage signaling. ARID1A deficiency sensitizes cancer cells to PARP inhibitors. Co-immunoprecipitation (ARID1A-ATR interaction), laser-induced DSB recruitment (live imaging), siRNA knockdown, in vitro and in vivo PARP inhibitor sensitivity assays Cancer discovery High 26069190
2017 ARID1A has context-dependent oncogenic and tumor suppressor functions in hepatocellular carcinoma. ARID1A gain-of-function promotes tumor initiation via increased CYP450-mediated oxidative stress, while ARID1A loss within established tumors decreases chromatin accessibility and reduces transcription of genes associated with migration, invasion, and metastasis. Liver-specific conditional KO and overexpression mouse models, ATAC-seq, RNA-seq, tumorigenesis assays Cancer cell High 29136504
2018 ARID1A is a transcriptional repressor at ER cis-regulatory elements; it recruits HDAC1 to enhancers in a FOXA1-dependent, ER-independent manner. ARID1A loss results in decreased HDAC1 binding, increased H4K acetylation, and subsequent BRD4-driven transcription and proliferation. Genome-wide CRISPR screen, ChIP-seq, ATAC-seq, HDAC1 Co-IP, H4K acetylation Western blotting Nature genetics High 31913353
2018 ARID1A loss suppresses pancreatic neoplasia partly through regulation of MYC activity and protein synthesis; ARID1A knockdown in human pancreatic ductal epithelial cells increases MYC expression, which is abolished by MYC knockdown. ChIP-seq showed increased H3K27ac at enhancers/promoters upon Arid1a loss. Conditional Arid1a KO mouse, siRNA/CRISPR knockdown in human cells, RNA-seq, ChIP-seq for H3K27ac Gut High 30315093
2019 ARID1A loss increases susceptibility to hepatic steatosis and insulin resistance; mechanistically, Arid1a deficiency impairs fatty acid oxidation by downregulating PPARα and altering the epigenetic landscape of metabolism genes. Hepatocyte-specific Arid1a KO mouse, GTT/ITT, ChIP, ATAC-seq, RNA-seq EBioMedicine High 30879920
2020 ARID1A inactivation causes resistance to ER degraders by facilitating a switch from ER-dependent luminal to ER-independent basal-like cells; this is mediated by loss of ARID1A-dependent SWI/SNF targeting to luminal lineage-determining TF (ER, FOXA1, GATA3) sites. ARID1A also regulates genome-wide ER-FOXA1 chromatin interactions. Epigenome CRISPR KO screen, ChIP-seq, ATAC-seq, patient sample analysis Nature genetics High 31932695
2020 ARID1A interacts with EZH2 via its carboxyl terminus and antagonizes EZH2-mediated suppression of IFN-responsive gene chromatin accessibility; ARID1A loss limits chromatin accessibility to IFN-responsive genes and impairs IFN gene expression. Co-immunoprecipitation (ARID1A-EZH2 interaction), ATAC-seq, IFN reporter assays, murine cancer models The Journal of clinical investigation High 32027624
2020 ARID1A deficiency in the endometrium leads to loss of TGF-β tumor suppressive function; ARID1A-deficiency/TGF-β axis inactivation promotes migration and invasion of PTEN-deleted endometrial tumor cells. Conditional KO mouse models (Arid1a, Pten), transcriptome analysis, functional migration/invasion assays, systems biology approach Nature communications High 32483112
2020 The E3 ligase TRIM32 and deubiquitinase USP11 control ARID1A protein stability via the ubiquitin-proteasome system in squamous cell carcinoma; TRIM32 stabilizes ARID1A while USP11 promotes its degradation. SDC2 is a downstream target of the TRIM32/USP11-ARID1A axis. siRNA knockdown, co-immunoprecipitation, ubiquitination assay, proliferation/invasion assays Cell reports Medium 31914402
2021 ARID1A loss leads to DNA replication stress associated with R-loops and transcription-replication conflicts; ARID1A-deficient cells show reduced TOP2A binding at R-loop sites. ARID1A KO human cell lines, R-loop immunofluorescence (S9.6 antibody), DRIP-seq, replication dynamics analysis PLoS genetics High 33826602
2021 SWI/SNF represses glutaminase (GLS1), and ARID1A inactivation upregulates GLS1, increasing glutamine utilization through the TCA cycle to support aspartate synthesis; this creates a metabolic dependency exploitable with GLS1 inhibition. ARID1A KO cell lines, ChIP, metabolic flux analysis, orthotopic and PDX mouse models, genetic OCCC mouse model Nature cancer High 34085048
2021 ARID1A loss promotes pancreatic neoplasia in a compartment-specific manner; in acinar cells, postnatal Arid1a silencing with oncogenic KrasG12D induces rapid irreversible reprogramming to mucinous PDAC precursor lesions, while embryonic Arid1a silencing preserves acinar identity. Inducible/reversible shRNA in KrasG12D mouse pancreas, lineage tracing, histological analysis eLife High 30014851
2021 ARID1A promotes both NHEJ and HR DNA DSB repair; it accumulates at DSBs and recruits RAD21 and CTCF to regulate chromatin loop formation; simultaneously facilitates transcription silencing at DSBs by recruiting HDAC1 and RSF1 to control chromatin accessibility and evict RNAPII. ChIP-seq, ATAC-seq, proximity ligation, NHEJ/HR reporter assays, ARID1A KO cells Nucleic acids research High 38587186
2021 ARID1A loss in HCC activates mTOR signaling (increased pS6) and SOX9 nuclear expression; mTORC1 physically interacts with ARID1A and promotes its ubiquitination and proteasomal degradation, driving YAP-dependent transcription and liver tumor development. Co-immunoprecipitation (mTORC1-ARID1A), ubiquitination assay, in vitro/in vivo tumor models, ChIP for YAP targets Cancer research High 34429326
2022 Inflammatory signaling activates IKKβ to phosphorylate ARID1A, leading to its β-TRCP-mediated degradation; ARID1A downregulation silences the A20 deubiquitinase enhancer, unleashing NF-κB signaling and CXCR2 ligand-mediated PMN-MDSC chemotaxis. Co-immunoprecipitation, phosphorylation assay, ChIP for A20 enhancer, prostate-specific conditional KO mouse, MDSC neutralization experiment Nature communications High 36435834
2021 TP53 and ARID1A mutations drive shared and distinct tumorigenic programs; ARID1A normally directly represses p53 pathway genes including ATF3 in vivo, and p53 pathway is activated following ARID1A loss in the endometrial epithelium. Conditional KO mouse models (Arid1a, TP53, PIK3CA), ChIP-seq, RNA-seq, functional invasion assays PLoS genetics High 34941867
2022 ARID1A loss in biliary cells suppresses TGF-β-Smad4 tumor suppressor pathway, enabling a biliary proliferative response; an ARID1A-TGF-β-Smad4 axis limits biliary epithelial response to oncogenic insults. Hepatocyte/biliary lineage-specific KO mouse models, cultured cells, proliferation/senescence assays, chromatin structure analysis, SMAD4 pathway analysis Cell reports High 36044839
2022 ARID1A deficiency in HCC upregulates USP9X and PRKAA2 (AMPKα2) by losing ARID1A-HDAC1 repressive complex at the USP9X promoter (via ARID1A C-terminal DUF3518 domain recruiting HDAC1), enabling survival under glucose starvation. CRISPR KO, mass spectrometry, Co-IP, GST pulldown, ChIP, luciferase reporter assay Cellular and molecular gastroenterology and hepatology High 35390516
2021 ARID1A interacts with and directly binds the transcriptional coactivators YAP and TAZ, sequestering them from their DNA-binding partner TEAD, thereby suppressing postnatal cardiomyocyte proliferation and promoting maturation. Conditional Arid1a KO in cardiomyocytes, ARID1A-YAP/TAZ direct binding assay, genome-wide transcriptome and epigenome (ATAC-seq, ChIP-seq) Nature communications High 37543677
2021 ARID1A physically interacts with progesterone receptor-A (PGR-A) but not PGR-B in mouse and human endometrium; uterine Arid1a KO mice are infertile due to loss of epithelial PGR signaling. Co-immunoprecipitation, proximity ligation assay (PLA), uterine-specific Arid1a KO mouse, immunostaining Biochemical and biophysical research communications Medium 33706098
2023 ARID1A loss represses expression of the glycolytic gene PKM, shifting glucose metabolism from aerobic glycolysis to dependence on TCA cycle and oxidative phosphorylation; ARID1A-deficient HCC cells show synthetic lethality with TCA cycle/cuproptosis-related gene inhibition. CRISPR-Cas9 synthetic lethality screen in ARID1A-deficient HCC cells, metabolic flux analysis, xenograft models, ChIP for PKM Cell reports. Medicine High 37939712
2023 ARID1A loss reduces chromatin accessibility and expression of rate-limiting mevalonate pathway enzymes (HMGCR, HMGCS1), creating a synthetic lethality with mevalonate pathway inhibitors and inducing immunomodulating pyroptosis. ATAC-seq, RNA-seq, orthotopic and genetic OCCC mouse models, immune checkpoint blockade combination experiments Cancer cell High 36963401
2024 ARID1A recognizes R-loops with high affinity in an ATM-dependent manner, recruits METTL3 and METTL14 to drive m6A methylation of R-loop RNA, which then facilitates RNase H1 recruitment to resolve R-loops and promote DNA end resection at DSBs. Co-immunoprecipitation, m6A-seq, R-loop immunofluorescence, RNase H1 recruitment assays, ARID1A/METTL3/METTL14 KO cells, DSB end resection assay Cell reports High 38358891
2024 ARID1A orchestrates SWI/SNF-mediated sequential binding of PU.1 and NF-kB at key genes for cytokine and CD40 signaling in B cells during germinal center response; ARID1A loss tilts GC cell fate toward immature IgM+CD80-PD-L2- memory B cells. Conditional Arid1a KO mouse, ChIP-seq, ATAC-seq, scRNA-seq, BCL2 oncogene cooperation model Cancer cell High 38458187
2024 ARID1A is required for IRF4 expression and physically associates with IRF4 protein on chromatin in multiple myeloma; Arid1a deletion in activated B cells disrupts IRF4-dependent transcriptional networks and blocks plasma cell differentiation. Conditional Arid1a KO in activated B cells, multi-omics (functional genomics screen, spatial proteomics, global chromatin mapping), Co-IP of ARID1A-IRF4 Cancer cell High 38906156
2024 ARID1A harbors a prion-like domain (PrLD) that drives liquid-liquid phase separation (LLPS) to form nuclear condensates at EWS/FLI1 target enhancers, inducing long-range chromatin architectural changes and activating oncogenic target genes in Ewing's sarcoma. Phase separation assay, live-cell imaging of condensates, genome-wide chromatin conformation (Hi-C), ChIP-seq, ATAC-seq, PrLD mutagenesis, patient sample analysis Nature communications High 39095374
2023 ARID1A loss decreases PgR (progesterone receptor) transcription by reducing SWI/SNF (ARID1A and BRG1) and H3K27ac occupancy at the PgR enhancer region in endometrial cells. ChIP-seq in isogenic ARID1A-/- and ARID1A+/+ endometrial cells, conditional Arid1a/Pten KO mouse model, immunohistochemistry in human samples Modern pathology High 36853791
2020 BAF250a/ARID1A regulates the physical interaction between OCT4 and β-CATENIN at promoters of key mesodermal lineage genes (MESP1, EOMES) during cardiac lineage differentiation from human ESCs; ARID1A deletion reduces OCT4-BRG1 interaction in mesoderm. Co-immunoprecipitation (OCT4-β-CATENIN interaction), ChIP at MESP1/EOMES/CCND2/CCND3 promoters, ARID1A KO in human ESCs, differentiation assays Frontiers in cell and developmental biology Medium 32039194
2018 The ARID domain of BAF250a has non-sequence-specific DNA binding; a conserved valine at position 1067, when mutated to glycine, destabilizes the ARID domain and abolishes DNA binding. The C-terminal BAF250_C region adopts an ARM-repeat fold. Comparative sequence analysis, computational modeling, in vitro mutagenesis of V1067G, structural stability and DNA binding affinity assays PloS one Medium 30307988

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer discovery 412 26069190
2008 ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proceedings of the National Academy of Sciences of the United States of America 275 18448678
2011 Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Human mutation 238 22009941
2014 The emerging roles of ARID1A in tumor suppression. Cancer biology & therapy 205 24618703
1997 Identification of protein p270/Tpr as a constitutive component of the nuclear pore complex-attached intranuclear filaments. The Journal of cell biology 198 9024684
2011 Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. The Journal of pathology 193 21590771
2017 Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. Cancer cell 187 29136504
2020 ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature genetics 181 31932695
2020 Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. The Journal of clinical investigation 151 32027624
2020 ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nature genetics 140 31913353
2021 Targeting ARID1A mutations in cancer. Cancer treatment reviews 136 34619527
2005 The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer research 128 16230384
2014 Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 126 24979463
2000 The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Molecular and cellular biology 106 10757798
2021 Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature cancer 102 34085048
2020 Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. Journal of Cancer 95 31949479
2010 Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Molecular and cellular biology 94 20086098
2016 Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 92 27562491
2022 ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nature communications 88 36435834
2018 ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene 86 29760405
2013 Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Advances in anatomic pathology 86 23232571
1998 p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Molecular and cellular biology 82 9584200
2018 Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell reports 81 29590609
2012 Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 78 22301703
2018 ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. Biochimica et biophysica acta. Reviews on cancer 74 30025943
2004 Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. International journal of cancer 74 15382044
2023 Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer cell 72 36963401
2022 Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. Journal of biomedical science 72 36123603
2018 SWI/SNF component ARID1A restrains pancreatic neoplasia formation. Gut 69 30315093
2020 Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature communications 64 32483112
2021 ARID1A regulates R-loop associated DNA replication stress. PLoS genetics 63 33826602
2021 The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? Frontiers in oncology 63 34671561
2023 Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. Cell reports. Medicine 58 37939712
2022 ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI insight 57 35852858
2012 SWI/SNF protein component BAF250a regulates cardiac progenitor cell differentiation by modulating chromatin accessibility during second heart field development. The Journal of biological chemistry 57 22621927
2020 The impact of ARID1A mutation on molecular characteristics in colorectal cancer. European journal of cancer (Oxford, England : 1990) 56 33080474
2015 Potential therapeutic targets in ARID1A-mutated cancers. Expert opinion on therapeutic targets 55 26125128
2020 TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell reports 47 31914402
1999 Iron modulates phenotypic variation and phosphorylation of P270 in double-stranded RNA virus-infected Trichomonas vaginalis. Infection and immunity 47 10417210
2019 Arid1a regulates insulin sensitivity and lipid metabolism. EBioMedicine 46 30879920
2024 The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability. Cell reports 44 38358891
2009 HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochemical and biophysical research communications 44 19486893
2024 ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic acids research 42 38587186
2012 Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment. Journal of Cancer 41 22408686
2023 ARID1A in cancer: Friend or foe? Frontiers in oncology 40 36890819
2022 Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability. Cancer research 40 34987057
2016 BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 40 27051059
2024 ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer cell 38 38458187
2018 Arid1a restrains Kras-dependent changes in acinar cell identity. eLife 37 30014851
2019 HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A. Cancers 35 31847141
2021 mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma. Cancer research 34 34429326
2017 ARID1A represses hepatocellular carcinoma cell proliferation and migration through lncRNA MVIH. Biochemical and biophysical research communications 34 28716731
2021 Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma. Cancers 33 33917230
2021 Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut 32 33785559
2021 Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis. PLoS genetics 32 34941867
2019 The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression. In vivo (Athens, Greece) 32 31028182
2015 The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma. Pathology oncology research : POR 31 26589513
2022 Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma. Cell reports 30 36044839
2020 Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 30 32791396
2019 Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response. Scientific reports 30 31796878
2022 Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma. Cellular and molecular gastroenterology and hepatology 29 35390516
2020 ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression. Cancer research 29 32015157
2016 (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. Molecular human reproduction 29 26832958
2016 Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. American journal of clinical pathology 29 27334809
2015 Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. Anticancer research 29 26637902
2024 IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell 28 38906156
2022 Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy. Cancer immunology, immunotherapy : CII 28 36369379
2020 Altered ARID1A expression in colorectal cancer. BMC cancer 28 32334542
2014 The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 28 24557437
2019 Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecologic oncology 27 31604667
2014 Baf250a orchestrates an epigenetic pathway to repress the Nkx2.5-directed contractile cardiomyocyte program in the sinoatrial node. Cell research 27 25145359
2015 Various ARID1A expression patterns and their clinical significance in gastric cancers. Human pathology 26 26826411
2024 Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 25 38833522
2013 Murine esBAF chromatin remodeling complex subunits BAF250a and Brg1 are necessary to maintain and reprogram pluripotency-specific replication timing of select replication domains. Epigenetics & chromatin 25 24330833
2023 Cardiomyocyte proliferation is suppressed by ARID1A-mediated YAP inhibition during cardiac maturation. Nature communications 24 37543677
2022 Roles of ARID1A variations in colorectal cancer: a collaborative review. Molecular medicine (Cambridge, Mass.) 24 35421925
2024 Prion-like domain mediated phase separation of ARID1A promotes oncogenic potential of Ewing's sarcoma. Nature communications 23 39095374
2022 Loss of Arid1a and Pten in Pancreatic Ductal Cells Induces Intraductal Tubulopapillary Neoplasm via the YAP/TAZ Pathway. Gastroenterology 23 35483445
2021 Arid1a regulates neural stem/progenitor cell proliferation and differentiation during cortical development. Cell proliferation 23 34562292
2013 Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2. Journal of the Chinese Medical Association : JCMA 23 23962610
2021 Chromatin remodeler Arid1a regulates subplate neuron identity and wiring of cortical connectivity. Proceedings of the National Academy of Sciences of the United States of America 22 34011608
2020 SWI/SNF Component BAF250a Coordinates OCT4 and WNT Signaling Pathway to Control Cardiac Lineage Differentiation. Frontiers in cell and developmental biology 22 32039194
2023 ARID1A mutations in cancer development: mechanism and therapy. Carcinogenesis 21 36882165
2017 ARID1A Expression is Down-Regulated by Oxidative Stress in Endometriosis and Endometriosis-Associated Ovarian Cancer. Translational oncogenomics 21 28469404
2025 Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer research 20 39652583
2015 ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component. Histopathology 19 25913291
2021 Role of ARID1A in the Regulation of Human Trophoblast Migration and Invasion. Reproductive sciences (Thousand Oaks, Calif.) 18 34255312
2020 Role and potential clinical utility of ARID1A in gastrointestinal malignancy. Mutation research. Reviews in mutation research 18 34083049
2018 Domain architecture of BAF250a reveals the ARID and ARM-repeat domains with implication in function and assembly of the BAF remodeling complex. PloS one 18 30307988
2022 Therapeutic significance of ARID1A mutation in bladder cancer. Neoplasia (New York, N.Y.) 17 35750014
2021 ARID1A and PGR proteins interact in the endometrium and reveal a positive correlation in endometriosis. Biochemical and biophysical research communications 17 33706098
2017 ARID1A gene knockdown promotes neuroblastoma migration and invasion. Neoplasma 17 28253716
2024 ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway. International journal of oncology 16 38873993
2021 ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms. Frontiers in oncology 16 34249744
2019 Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity. International journal of molecular sciences 16 31731647
2023 The effects of ARID1A mutation in gastric cancer and its significance for treatment. Cancer cell international 15 38008753
2020 Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma. Journal of gynecologic oncology 15 33185044
2016 ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin. Experimental and therapeutic medicine 15 28105136
2023 ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 14 36853791
2022 Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ 14 35070505